Compare Devon Energy Corp (DVN) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Devon Energy Corp vs Regeneron Pharmaceuticals Inc — how do they compare? Devon Energy Corp trades at $45.35 (market cap $49.90B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is the larger of the two by market cap, and Devon Energy Corp pays the higher dividend (2.82%). Which is the better fit depends on your goals.
| DVN | REGN | |
|---|---|---|
Market Cap | $49.90B | $83.19B |
Sector | Energy | Health |
52-Week High | $52.07 | $812.27 |
52-Week Low | $31.74 | $555.51 |
Enterprise Value | $60.63B | $77.90B |
Dividend Yield | 2.82% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Devon Energy (DVN) trades at $42.98, down 0.3% with a bearish technical signal. The company reported strong Q2 2026 results, beating EPS estimates by 21% and revenue by 18%, while raising its dividend 33% and accelerating debt reduction. Valuation metrics appear attractive with P/E of 9.34 and EV/EBITDA of 6.59, though net income margins have declined from 31.4% in 2022 to 15.4% in 2025.
The outlook remains positive with 71% analyst buy ratings and a $61.91 consensus price target representing 44% upside. Key catalysts include merger synergies from Coterra integration and strong free cash flow generation supporting shareholder returns. Risks include oil price volatility and execution of the $1B+ synergy target by 2027.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
